Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 496.78% and ...

The monthslong battle over the future of the weight-loss drug industry is headed for a climax this week, when the Food and ...

Investors' focus could, however, shift back onto the possible market impacts of GLP-1 agonists in 2025, particularly as a result of a major expansion of current supplies after Novo Nordisk was given a ...

The tech company estimates that its investment will create 100,000 jobs focused on AI and emerging technologies. Canal+'s shares fell on the London Stock Exchange and Havas's stock rose on Euronext ...

Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with ...

The biotech's candidate VK2735 belongs to the same class of drugs as Eli Lilly's star weight loss drug Zepbound -- it acts on ...

Aucatzyl is a chimeric antigen receptor (CAR) T-cell therapy, a type of therapy that uses genetic modification to train the ...

FSAD is clinically analogous to erectile dysfunction in men.To date, there are no FDA-approved pharmacological treatments for ...

If your heart rate increases each time you hear the word "injection," you’re not alone. Every 1 in 4 adults has a fear of ...

Neurocrine Biosciences stock jumped Monday after the company won FDA approval for the first new treatment for an adrenal ...

Telehealth firm Ro will offer low-cost, single-dose vials of Lilly's obesity drug Zepbound, the first alternative to the new LillyDirect DTC channel. Join the conversation, on Tuesday 28th January ...